Preclinical Alzheimer Disease
Conditions
Interventions
Experimental Group:Shenqiyizhi Keli, Pro, Bid
Control Group:Aricept (donepezil hydrochloride), Pro, Qd
Sponsors
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medicine
Eligibility
Sex/Gender
All
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Outpatients or inpatients aged 50-80 years and community elderly population, regardless of gender, education level >= 6 years; 2. Determined cognitive impairment based on neuropsychological scale and clinical symptoms (at least one cognitive field score below 1.0SD); 3. Meet the NIA-AA preclinical Alzheimer Disease diagnostic criteria.
Exclusion criteria
Exclusion criteria: 1. Participants with severe caridiac, liver, and kidney dysfunction; 2. Participants with other mental and neurological disorders and malignant tumors; 3. The Geriatric Depression Scale (GDS) score <10 points, excluding cognitive impairment due to emotions; 4. Those who have participated or are participating in other drug trials within three months before being selected; 5. Poor compliance, severe illness or being dying as well as expected survival time is less than 1 year, who cannot complete the course of treatment; 6. Use other cognitive-improving drugs such as ChEIs or other psychotropic drugs within the past three months; 7. MRI contraindications.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Alzheimer's disease assessment scale, ADAS-cog;Auditory Verbal Learning Test, AVLT;Mini-Mental Status Examination, MMSE; | — |
Secondary
| Measure | Time frame |
|---|---|
| Rey-Osterrich Complex Figure Test;Activity of daily living;Trail Making Test;Clock Drawing Test;Symbol Digit Modalities Test;Verbal Fluency Test;Boston Naming Test;Network value of white matter fiber tracts; | — |
Countries
China
Contacts
Public ContactLi He
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medicine
Outcome results
None listed